JP7382348B2 - AhRモジュレータ - Google Patents

AhRモジュレータ Download PDF

Info

Publication number
JP7382348B2
JP7382348B2 JP2020564046A JP2020564046A JP7382348B2 JP 7382348 B2 JP7382348 B2 JP 7382348B2 JP 2020564046 A JP2020564046 A JP 2020564046A JP 2020564046 A JP2020564046 A JP 2020564046A JP 7382348 B2 JP7382348 B2 JP 7382348B2
Authority
JP
Japan
Prior art keywords
methyl
phenyl
trifluoromethyl
quinazolin
dihydropyrazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020564046A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512954A (ja
JP2021512954A5 (cg-RX-API-DMAC7.html
Inventor
アラム ムザファル
プレイク ベック ヒラリー
パトリック ディロン マイケル
ゴンザレスーロペス マルコス
クリフォード サットン, ジュニア ジェイムズ
Original Assignee
アイディアヤ バイオサイエンシーズ,インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイディアヤ バイオサイエンシーズ,インコーポレイティド filed Critical アイディアヤ バイオサイエンシーズ,インコーポレイティド
Publication of JP2021512954A publication Critical patent/JP2021512954A/ja
Publication of JP2021512954A5 publication Critical patent/JP2021512954A5/ja
Application granted granted Critical
Publication of JP7382348B2 publication Critical patent/JP7382348B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Amplifiers (AREA)
  • Supplying Of Containers To The Packaging Station (AREA)
JP2020564046A 2018-02-06 2019-02-05 AhRモジュレータ Active JP7382348B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862626739P 2018-02-06 2018-02-06
US62/626,739 2018-02-06
US201962793260P 2019-01-16 2019-01-16
US62/793,260 2019-01-16
PCT/US2019/016705 WO2019156987A1 (en) 2018-02-06 2019-02-05 AhR MODULATORS

Publications (3)

Publication Number Publication Date
JP2021512954A JP2021512954A (ja) 2021-05-20
JP2021512954A5 JP2021512954A5 (cg-RX-API-DMAC7.html) 2022-02-15
JP7382348B2 true JP7382348B2 (ja) 2023-11-16

Family

ID=65494575

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020564046A Active JP7382348B2 (ja) 2018-02-06 2019-02-05 AhRモジュレータ

Country Status (10)

Country Link
US (3) US10815250B2 (cg-RX-API-DMAC7.html)
EP (2) EP4219495A1 (cg-RX-API-DMAC7.html)
JP (1) JP7382348B2 (cg-RX-API-DMAC7.html)
CN (1) CN111683950B (cg-RX-API-DMAC7.html)
CA (1) CA3090150A1 (cg-RX-API-DMAC7.html)
DK (1) DK3749669T6 (cg-RX-API-DMAC7.html)
ES (1) ES2946632T7 (cg-RX-API-DMAC7.html)
FI (1) FI3749669T6 (cg-RX-API-DMAC7.html)
TW (1) TWI840343B (cg-RX-API-DMAC7.html)
WO (1) WO2019156987A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019018562A1 (en) * 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUND AS MODULATORS OF AHR
EP4219495A1 (en) 2018-02-06 2023-08-02 Ideaya Biosciences, Inc. Ahr modulators
KR20260057216A (ko) * 2019-11-22 2026-04-27 세일 바이오메디슨스, 인크. Ahr 길항제로서의 피리도피리미디논 유도체
MX2022012739A (es) * 2020-04-17 2022-11-07 Dong A St Co Ltd Derivados de piridopirimidinona y su uso como moduladores del receptor de hidrocarburos de arilo.
WO2021236717A1 (en) 2020-05-20 2021-11-25 Senda Biosciences, Inc. Fused imidazole derivatives as ahr antagonists
CN114181212B (zh) * 2020-09-15 2023-06-06 山东轩竹医药科技有限公司 哒嗪酮类AhR抑制剂
WO2022081649A1 (en) * 2020-10-13 2022-04-21 Senda Biosciences, Inc. Biomarkers related to immune checkpoint inhibitor therapy and methods of using the same
WO2023020512A1 (zh) * 2021-08-16 2023-02-23 成都奥睿药业有限公司 取代的吡啶类似物、其制备方法及作为ahr调节剂的用途
CN118076613A (zh) * 2021-09-02 2024-05-24 捷豹治疗有限公司 可用于调节AhR信号传导的化合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011521958A (ja) 2008-05-27 2011-07-28 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム Wntタンパク質シグナル伝達阻害剤
JP2013543504A (ja) 2010-10-14 2013-12-05 イムナール アクティエボラーグ Ahr活性化因子としての1,2‐ジヒドロ‐4‐ヒドロキシ‐2‐オキソ‐キノリン‐3‐カルボキシアニリド
JP2017520561A (ja) 2014-06-27 2017-07-27 ノグラ ファーマ リミテッド アリール受容体モジュレーターならびにその作製および使用方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20010795A2 (en) 1999-04-28 2003-02-28 Aventis Pharma Gmbh Di-aryl acid derivatives as ppar receptor ligands
CA2454080A1 (en) 2001-08-13 2003-02-27 Robert Edward Detlefsen Ultraviolet light absorbers
US7098222B2 (en) 2004-05-12 2006-08-29 Abbott Laboratories Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US20050256118A1 (en) 2004-05-12 2005-11-17 Altenbach Robert J Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
CR9465A (es) 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
WO2007016525A2 (en) 2005-07-29 2007-02-08 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
CA2700988A1 (en) 2006-09-27 2008-05-08 Surface Logix, Inc. Rho kinase inhibitors
UA106037C2 (uk) 2008-02-04 2014-07-25 Мерк'Юрі Терап'Ютікс, Інк. Модулятори ampk (амф-активованої протеїнкінази)
AU2009243006B2 (en) 2008-05-01 2013-03-21 Sirtris Pharmaceuticals, Inc. Quinolines and related analogs as sirtuin modulators
MX2011009568A (es) 2009-03-09 2011-12-06 Surface Logix Inc Inhibidores de la rho cinasa.
WO2010148350A1 (en) * 2009-06-18 2010-12-23 Cornell University Photoproducts of tryptophan, their synthesis and uses thereof
US10314810B2 (en) * 2010-07-27 2019-06-11 Trustees Of Boston University Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
USRE47009E1 (en) 2011-02-01 2018-08-28 The Children's Hospital Of Philadelphia HDAC inhibitors and therapeutic methods using the same
WO2013086436A1 (en) 2011-12-08 2013-06-13 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
JP6980534B2 (ja) 2015-06-25 2021-12-15 ザ チルドレンズ メディカル センター コーポレーション 造血幹細胞の増大、富化、および維持に関する方法および組成物
WO2017184547A1 (en) 2016-04-18 2017-10-26 New York University Quinoline compounds as modulators of rage activity and uses thereof
TWI674260B (zh) 2017-02-01 2019-10-11 德商菲尼克斯製藥股份有限公司 芳基烴受體(AhR)調節劑化合物
TWI752155B (zh) 2017-02-01 2022-01-11 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物
TW201835070A (zh) 2017-02-21 2018-10-01 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物
MX2019012431A (es) 2017-04-21 2020-08-03 Ikena Oncology Inc Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
WO2019018562A1 (en) 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUND AS MODULATORS OF AHR
EP4219495A1 (en) 2018-02-06 2023-08-02 Ideaya Biosciences, Inc. Ahr modulators
US20210254006A1 (en) 2018-06-06 2021-08-19 Ideaya Biosciences, Inc. Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011521958A (ja) 2008-05-27 2011-07-28 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム Wntタンパク質シグナル伝達阻害剤
JP2013543504A (ja) 2010-10-14 2013-12-05 イムナール アクティエボラーグ Ahr活性化因子としての1,2‐ジヒドロ‐4‐ヒドロキシ‐2‐オキソ‐キノリン‐3‐カルボキシアニリド
JP2017520561A (ja) 2014-06-27 2017-07-27 ノグラ ファーマ リミテッド アリール受容体モジュレーターならびにその作製および使用方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Neunhoeffer, Otto; Ulrich, Henri,Synthesis and fluorescence of quinoline-substituted 1,3,5-triphenylpyrazolines,Chemische Berichte,1955年,88,,1123-33
REGISTRY(STN)[online],2008年,CAS 登録番号:1052645-43-8
REGISTRY(STN)[online],2018年,CAS 登録番号:1052645-43-8他計65化合物

Also Published As

Publication number Publication date
CN111683950A (zh) 2020-09-18
EP4219495A1 (en) 2023-08-02
TWI840343B (zh) 2024-05-01
EP3749669A1 (en) 2020-12-16
FI3749669T6 (fi) 2024-11-13
US12258354B2 (en) 2025-03-25
JP2021512954A (ja) 2021-05-20
US20190270754A1 (en) 2019-09-05
US11407764B2 (en) 2022-08-09
ES2946632T7 (es) 2025-03-04
US20210002297A1 (en) 2021-01-07
CA3090150A1 (en) 2019-08-15
US20230039955A1 (en) 2023-02-09
US10815250B2 (en) 2020-10-27
FI3749669T3 (fi) 2023-05-26
TW201945362A (zh) 2019-12-01
WO2019156987A1 (en) 2019-08-15
ES2946632T3 (es) 2023-07-21
DK3749669T6 (da) 2024-11-18
EP3749669B1 (en) 2023-03-08
EP3749669B3 (en) 2024-09-04
DK3749669T3 (da) 2023-06-06
CN111683950B (zh) 2024-04-16

Similar Documents

Publication Publication Date Title
US12258354B2 (en) AhR modulators
JP7624476B2 (ja) A2a/a2b阻害剤としてのイミダゾピリミジン及びトリアゾロピリミジン
US12570672B2 (en) Macrocyclic compounds and methods of use
CN112166110B (zh) Shp2磷酸酶抑制剂及其使用方法
JP2020183397A (ja) Btk活性阻害剤としてのヘテロアリールピリドン及びアザピリドン化合物
JP6716586B2 (ja) Fgfr4阻害剤としての二環式複素環
WO2020010197A1 (en) Fused pyrazine derivatives as a2a / a2b inhibitors
AU2013272701A1 (en) Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors
TW202136270A (zh) 環狀化合物及其使用方法
US12319671B2 (en) 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof
EP4284804A1 (en) Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders
WO2019156989A1 (en) COMPOUNDS AND METHODS FOR THE MODULATION OF AhR
CN117120442A (zh) 用于治疗癌症、自身免疫性病症和炎性病症的三环化合物
HK40042159B (en) Ahr modulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220204

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230804

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231010

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231106

R150 Certificate of patent or registration of utility model

Ref document number: 7382348

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150